Demant is increasing its expectations in its financial guidance for the whole of 2021 in connection with the interim management statement covering the year to date released on Tuesday.
The company now aims for organic growth between 24 and 28 percent and an operating result before interest and tax (EBIT) of DKK 3-3.3bn (USD 485.5-534m).
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.